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ple (n  20,088) of adult residents from the Baltimore, MD
and Chicago, IL areas was contacted by phone, of whom
7,691 met occupation eligibility criteria. Respondents were
randomized to one of the six interviews at the time of con-
tact. Interviews were compared on the basis of estimates of
work loss and variation in estimates of work loss associated
with recall period and version.
RESULTS: Interviews varied in average length from 9.2
minutes (V3) to 15.1 minutes (V1). The participation rate
(66%) did not vary with the version. Estimates of work
loss varied with recall period and version. The mean total
hours/week of lost productive work time was lower for
interviews using a four-week compared to a one-week re-
call period. V3 of the interviews was the most discrim-
inating for illness-related work-loss estimates. For ex-
ample, individuals with allergic rhinitis (AR) reported
significantly more lost productive time at work due to
not feeling well compared to controls and a stronger rela-
tion between severity of AR and work loss.
CONCLUSION: Variation in relatively short recall peri-
ods influences estimates of work loss. Interview version 3
required the least time to administer and was the most
discriminating in terms of work-loss estimates by illness
status and illness severity.
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OBJECTIVE: To collect information on knowledge of
asthma by patients (pts), on its management and outcomes.
METHODS: multi-center, cross-sectional survey. Patients
(pts) were administered a questionnaire derived from the
one used in the survey “Asthma Insights & Reality in Eu-
rope” (A.I.R.E.). The questionnaire was adapted for ad-
ministration during a visit, instead of by phone as done
during A.I.R.E.
RESULTS: During the second half of 2000, 105 pneu-
mologists administered the questionnaire to 1017 asth-
matic pts (972 fully evaluable). Urban population repre-
sented 53% of the sample, males were 44%, mean age
was 44 years, and 35% suffered from seasonal asthma.
Relatives suffering from asthma were reported by 39% of
pts. Most pts (80%) believed that the number of Italian
asthmatics had increased during the last decade. Those
who rated their health status as at least good were 60%.
Fifty three percent thought that their asthma was better
today than 10 years ago. During the last 12 months, se-
vere symptoms were reported by 44% of pts, 11% of pts
spent at least one night in hospital, 16% reported access-
ing an emergency department, and 34% had an unsched-
uled visit. During the last four weeks, asthma was re-
ported as very good/good by 53%. In the same time,
72% of pts reported symptoms of various severity, and
40% of pts had night awakening. The peak flow meter
was known by 54% of pts. Thirty two percent of pts
owned one, but more than 50% of pts did not use it or
used it only when symptoms appeared. Half of pts under-
went lung functionality tests during the last 12 months.
CONCLUSION: Our data suggest that asthma manage-
ment does not usually fit the GINA guidelines. Health
status reported by pts does not always correspond with
symptom severity assessed by doctors. The hospitaliza-
tion rate and unscheduled visits due to asthma seem to be
higher than expected.
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OBJECTIVES: To determine the cost-effectiveness of ba-
sic monotherapy for bronchial asthma in children with
nedocromil sodium with or without specific immunotro-
pic therapy (SIT).
METHODS: Criteria for effectiveness were the number
of asymptomatic days per year and a complex estimation
by A. Zemskov (1997) which includes dynamics, clinical
and immunochemical markers of allergic inflammation.
Direct and indirect costs were calculated using data from
patient diaries with daily recording of medication and
medical care. We observed 100 children with moderately
severe asthma. The first group received monotherapy
with nedocromil sodium. The second group received
nedocromil sodium with SIT domestic allergens.
RESULTS: The study revealed that use of nedocromil so-
dium in 84.0 
 4.23% of the children provided 327.24 

1.04 asymptomatic days per year. The cost of one asymp-
tomatic day was 15.44 
 0.26 rubles. The use of SIT in
the first year of treatment improved the control of
asthma, and the number of asymptomatic days per year
was 333,8 
 1,01. The cost of one asymptomatic day in
this group is 12,04 
 0,28 rubles. Incremental cost-effec-
tiveness ratio in group with SIT was 171,71. This com-
plex analysis of the index with determination of clinico-
immunological effectiveness was 944,41.
CONCLUSIONS: Our investigation showed that SIT in
children with moderately severe asthma improved the ef-
fectiveness of basic therapy and reduced expenditures.
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Ipratropium, a short-acting anticholinergic bronchodila-
tor, is frequently prescribed for the maintenance treat-
ment of COPD. Tiotropium is a new, once-daily bron-
chodilator.
OBJECTIVE: To compare the costs and consequences of
tiotropium versus ipratropium in COPD patients with a
FEV 1 65% of predicted normal.
METHODS: The cost-consequence analysis was part of a
one-year, randomized, controlled, double-blind clinical
trial in the Netherlands and Belgium. Consequences were
expressed as the number of COPD exacerbations, the
number of patients with a minimal clinically relevant im-
provement in the St. George’s Respiratory Questionnaire
(SGRQ), and the number of effectively treated patients.
A societal perspective was adopted when calculating
COPD-related direct health-care costs. Multiple imputa-
tion (SOLAS) was used to impute all missing data.
RESULTS: Tiotropium was associated with a 27% re-
duction in exacerbations (p  0.03). The number of pa-
tients with a clinically relevant improvement in SGRQ af-
ter one year of treatment was 16% higher in tiotropium
(p  .001). The proportion of effectively treated patients
was 21% higher (p  .001). Across all categories, health-
care resource use was consistently lower for tiotropium
than for ipratropium. There was a 47% reduction (p 
0.07) in the number of hospital admissions and a 36%
reduction (p  0.03) in the number of unscheduled visits
to physicians and other caregivers. The use of concomi-
tant medication was comparable in both groups. COPD-
related health-care costs were estimated to be Euro 1310
in ipratropium and Euro 1065 in tiotropium. Hence, an-
nual savings were estimated to be Euro 245 with a 95%
CI ranging from 656 to 167. This estimate excludes
the costs of the study medications, since the price of
tiotropium still has to be set.
CONCLUSION: This cost-consequence analysis favors
the new once daily bronchodilator tiotropium over iprat-
ropium on all relevant outcome measures.
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OBJECTIVE: To determine if lost productive work time
differed between individuals with and without AR symp-
toms and by severity of AR symptoms. Work loss was
evaluated as: a) missed workdays; b) missed hours, and c)
reduced productivity on days at work while not feeling
well.
METHODS: Three different phone interviews were de-
veloped to quantify illness-related work loss. Version 1
(V1) included a lengthy direct assessment of work loss.
Version 2 (V2) was an abridged version of V1. Version 3
(V3) included a brief indirect assessment of work loss.
Two different recall periods, at one week and at four
weeks, were used for each version of the interview. A
convenience sample (n  20,088) of adult residents from
the Baltimore, MD and Chicago, IL areas was contacted
by phone, of whom 7,691 met occupation eligibility cri-
teria. The interview included health questions to screen
for AR symptoms and to determine AR severity.
RESULTS: The dominant source of health-related work
loss among all respondents was in total hours of reduced
productive work time on days at work when not feeling
well, rather than missed full days of work. We compared
individuals with AR symptoms (n  1,596) to controls
without AR symptoms on the basis of estimates of total
hours of lost productive work time per week by interview
version. AR cases reported significantly more lost pro-
ductive work hours per week than controls. The observed
differences between cases and controls per week were 1.8
hours (V1), 2.1 hours (V2), and 3.1 hours (V3) (p  .05).
Among moderate-to-severe AR cases, the observed differ-
ences per week increased to 4.4 hours (V1), 5.7 hours
(V2), and 6.5 hours (V3).
CONCLUSION: Individuals with AR symptoms re-
ported significantly more lost productive time at work on
days at work when not feeling well than controls. Hours
of lost productive work time per week increased with in-
creased severity of AR symptoms.
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OBJECTIVES: To assess the impact of an intervention
helping physicians in the management of asthma patients
(APs).
METHODS: A program was designed to help physicians
in the management of APs that includes an education
program (EP) and a computer application (CA) advising
on therapeutic decisions. The EP was devoted to teach
patients to distinguish worsening symptoms requiring a
hospital emergency visit from those that could be self-
managed, and to ensure correct self-administration/self-
control of therapy. The CA implements the Spanish rec-
ommendations for the management of APs that physi-
cians may follow at their discretion. A naturalistic, con-
trolled, cluster-randomized study was designed to assess
the long-term (one-year) impact of the intervention on
health-related quality of life as measured by the St.
George’s Respiratory Questionnaire (SGRQ), on direct
and indirect costs, and on satisfaction and clinical out-
comes. We also assessed physicians’ adherence to the rec-
ommendations. Twenty-two physicians (11 GPs, 11 pneu-
